Chronic Kidney Disease - Pipeline Assessment and Market Forecasts to 2016

Introduction

GlobalData, the industry analysis specialist’s new report, “Chronic Kidney Disease - Pipeline Assessment and Market Forecasts to 2016” is an essential source of information and analysis on the global chronic kidney disease market. The report identifies the key trends shaping and driving the global chronic kidney disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global chronic kidney disease sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key driver and challenges of the global CKD market. Its scope includes:
- Annualized global chronic kidney disease market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
- Analysis of the current and future market competition in the global chronic kidney disease market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with chronic kidney disease.

Highlights

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global chronic kidney disease market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global chronic kidney disease market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global chronic kidney disease market landscape? – Identify, understand and capitalize.

Report Highlights
Novartis AG
Reata Pharmaceuticals, Inc
Mitsubishi Tanabe Pharma Corporation
Cytochroma Inc
Keryx Biopharmaceuticals
Astellas Pharma Inc.
FibroGen
[Cerrar las informaciones del articulo de mercado]

TABLE OF CONTENTS

1 Table of Contents
1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Chronic Kidney Disease Market: Introduction 4
2.1 GlobalData Pipeline Report Guidance 4
3 Chronic Kidney Disease Market: Market Characterization 5
3.1 Chronic Kidney Disease Market Size 5
3.2 Chronic Kidney Disease Market Forecast and CAGR 5
3.3 Drivers and Barriers for the Chronic Kidney Disease Market 6
3.3.1 Drivers for the Chronic Kidney Disease Market 6
3.3.2 Barriers for the Chronic Kidney Disease Market 7
3.4 Opportunity and Unmet Need 7
3.5 Key Takeaway 8
4 Chronic Kidney Disease Market: Competitive Assessment 9
4.1 Overview 9
4.2 Strategic Competitor Assessment 9
4.3 Product Profiles of the Major Marketed Products in the Chronic Kidney Disease Market 10
4.3.1 Renagel (sevelamer hydrochloride) 10
4.3.2 Renvela (sevelamer carbonate) 11
4.3.3 Sensipar (cinacalcet hydrochloride) 11
4.3.4 Feraheme (ferumoxytol) 12
4.3.5 Fosrenol (lanthanum carbonate hydrate) 13
4.4 Key Takeaway 15
5 Chronic Kidney Disease Market: Pipeline Assessment 16
5.1 Overview 16
5.2 Strategic Pipeline Assessment 16
5.2.1 Technology Trends Analytic Framework 16
5.3 Chronic Kidney Disease Therapeutics – Promising Drugs under Clinical Development 18
5.4 Molecule Profile for Promising Drugs under Clinical Development 19
5.4.1 Bardoxolone methyl 19
5.4.2 MCI-196 20
5.4.3 CTA018 20
5.4.4 AST-120 (Kremezin) 21
5.5 Chronic Kidney Disease Therapeutics Market – Clinical Pipeline by Mechanism of Action 23
5.6 Chronic Kidney Disease Pipeline – Pipeline by Clinical Phases of Development 24
5.6.1 Chronic Kidney Disease Therapeutics – Phase III Clinical Pipeline 25
5.6.2 Chronic Kidney Disease Therapeutics – Phase II Clinical Pipeline 26
5.6.3 Chronic Kidney Disease Therapeutics – Phase I Clinical Pipeline 27
5.6.4 Chronic Kidney Disease Therapeutics – Preclinical Pipeline 27
5.6.5 Discontinued / Suspended Drugs for Chronic Kidney Disease 28
5.7 Key Takeaway 28
6 Chronic Kidney Disease Market: Implications for Future Market Competition 29
Chronic Kidney Disease Market: Future Players in the Chronic Kidney Disease Market 31
6.1 Introduction 31
6.2 Novartis AG 31
6.2.1 Company Overview 31
6.2.2 Kidney Disease Portfolio 32
6.3 Reata Pharmaceuticals, Inc 32
6.3.1 Company Overview 32
6.3.2 Kidney Disease Portfolio 32
6.4 Mitsubishi Tanabe Pharma Corporation 32
6.4.1 Company Overview 32
6.4.2 Business Description 33
6.4.3 Kidney Disease Portfolio 34
6.5 Cytochroma Inc 34
6.5.1 Company Overview 34
6.5.2 Kidney Disease Portfolio 34
6.6 Keryx Biopharmaceuticals 34
6.6.1 Company Overview 34
6.6.2 Business Description 35
6.6.3 Kidney Disease Portfolio 35
6.7 Astellas Pharma Inc. 36
6.7.1 Company Overview 36
6.7.2 Business Description 36
6.7.3 Kidney Disease Portfolio 37
6.8 FibroGen 37
6.8.1 Company Overview 37
6.8.2 Chronic Kidney Disease Portfolio 37
7 Chronic Kidney Disease Market: Appendix 38
7.1 Market Definition 38
7.2 Scope of Pipeline Research 38
7.3 Abbreviations 38
7.4 Research Methodology 40
7.4.1 Coverage 40
7.4.2 Secondary Research 41
7.4.3 Forecasting 41
7.4.4 Primary Research 44
7.4.5 Expert Panels 44
7.5 Contact Us 44
7.6 Disclaimer 44
7.7 Sources 45
[Cerrar la tabla de contenidos]

LIST OF TABLES

1.1 List of Tables
Table 1: Chronic Kidney Disease, Global, Revenue ($bn), 2001–2009 5
Table 2: Chronic Kidney Disease, Global, Market Forecast ($bn), 2009–2016 6
Table 3: Marketed Product Analysis for Chronic Kidney Disease, 2010 15
Table 4: Chronic Kidney Disease Therapeutics – Most Promising Drugs under Clinical Development, 2010 18
Table 5: Chronic Kidney Disease Pipeline, Phase III, 2010 25
Table 6: Chronic Kidney Disease Pipeline, Phase II, 2010 26
Table 7: Chronic Kidney Disease Pipeline, Phase I, 2010 27
Table 8: Chronic Kidney Disease Pipeline, Preclinical Phase, 2010 27
Table 9: Chronic Kidney Disease Pipeline, Discontinued / Suspended Drugs, 2010 28
Table 10: Novartis AG – Kidney Disease Portfolio, 2010 32
Table 11: Reata Pharmaceuticals – Kidney Disease Portfolio, 2010 32
Table 12: Mitsubishi Tanabe Pharma Corporation – Kidney Disease Portfolio, 2010 34
Table 13: Cytochroma – Kidney Disease Portfolio, 2010 34
Table 14: Keryx Biopharmaceuticals – Kidney Disease Portfolio, 2010 35
Table 15: Astellas – Kidney Disease Portfolio, 2010 37
Table 16: Fibrogen – Kidney Disease Portfolio, 2010 37
LIST OF FIGURES

1.2 List of Figures
Figure 1: Chronic Kidney Disease, Global, Revenue ($bn), 2001–2009 5
Figure 2: Chronic Kidney Disease, Global, Market Forecast ($bn), 2009–2016 6
Figure 3: Opportunity and Unmet Need in the Chronic Kidney Disease Market, 2010 8
Figure 4: Strategic Competitor Assessment of the Marketed Products for Chronic Kidney Disease, 2010 9
Figure 5: Technology Trends Analytic Framework of the Chronic Kidney Disease Pipeline, 2010 17
Figure 6: Technology Trends Analytic Framework of the Chronic Kidney Disease Pipeline – Description, 2010 17
Figure 7: Chronic Kidney Disease Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010 23
Figure 8: Chronic Kidney Disease Pipeline by Phase of Clinical Development, 2010 24
Figure 9: Implications for Future Market Competition in the Chronic Kidney Disease Market, 2010 29
Figure 10: Chronic Kidney Disease Therapeutics Market – Clinical Pipeline by Company, 2010 31
Figure 11: GlobalData Methodology 40
Figure 12: GlobalData Market Forecasting Model 43
[Ocultar lista de tablas / figuras]